ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome [PDF]
, 2023 Patients suffering from acute coronary syndrome (ACS) present a high risk of recurrence and new adverse cardiovascular events after hospital discharge.
Caldarola P. +15 more
core +1 more source
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis [PDF]
Journal of Clinical Medicine, 2021 The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%–20% of high- and very-high-risk patients do not reach their LDL-C targets.
Sylwester Rogula +6 more
openaire +2 more sources
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions. [PDF]
MedComm (2020)Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9‐i) primarily lower LDL‐cholesterol (LDL‐C) by blocking PCSK9‐mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearance. Beyond LDLR‐dependent effects, PCSK9‐i exert multiple benefits via LDLR‐independent pathways.
Kuang J, Hao L, Zhang M, Yang Z.
europepmc +2 more sources
Canadian Journal of Health Technologies, 2022 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
Novel Drugs Approved in 2021-2022 [PDF]
, 2022 This article provides an abbreviated overview of the newly Federal Drug Administration (FDA)approved novel drugs of 2021-2022 with their respective approved indication(s).
Do, Michael +3 more
core +2 more sources
Evaluating Value Beyond Efficacy: A Meta-Analytic Assessment of Inclisiran's Cost-Effectiveness in Cardiovascular Prevention. [PDF]
Healthcare (Basel)Background/Objectives: Cardiovascular diseases continue to be the foremost global cause of morbidity and mortality, representing about 40% of all causes of death.
Maștaleru A +6 more
europepmc +2 more sources
Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-The future is here [PDF]
, 2023 Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing
Hermel, Melody +4 more
core +2 more sources
#1736 Treatment with inclisiran in patients with nonfamilial hypercholesterolemia and chronic kidney disease [PDF]
Nephrology, Dialysis and TransplantationPatients with chronic kidney disease have a high incidence of morbidity and mortality from cardiovascular causes. Among the most significant cardiovascular risk factors is undoubtedly hypercholesterolemia, especially elevated cholesterol-LDL levels.
Andrea Dello Strologo +7 more
openalex +2 more sources
Current States of Clinical Perspectives on Medication for Dyslipidemia [PDF]
, 2021 Current topics for dyslipidemia are described. Elderly people receiving statin (n=326,981) for 6.8 years showed reduced hazard ratio (HR) as total mortality 0.75, and cardiovascular mortality 0.80.
Bando, Hiroshi
core
Cardiovascular ResearchAims Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials.
R. S. Wright +11 more
semanticscholar +1 more source